title: Who should sponsor sleep disorders pharmaceutical trials?
authors.forename: Daniel F
authors.initials: DF
authors.lastname: Kripke
mesh_terms: D016907:Adverse Drug Reaction Reporting Systems; D053961:Azabicyclo Compounds / Q000009:adverse effects / Q000627:therapeutic use; D015982:Bias; D016265:Conflict of Interest; D018849:Controlled Clinical Trials as Topic / Q000941:ethics* / Q000706:statistics & numerical data; D004345:Drug Industry / Q000941:ethics*; D000069582:Eszopiclone; D006801:Humans; D006993:Hypnotics and Sedatives / Q000009:adverse effects / Q000627:therapeutic use*; D009316:National Institutes of Health (U.S.); D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use; D012109:Research Support as Topic / Q000941:ethics*; D012148:Restless Legs Syndrome / Q000188:drug therapy; D012893:Sleep Wake Disorders / Q000188:drug therapy*; D016896:Treatment Outcome; D014481:United States; D014493:United States Department of Veterans Affairs; D014486:United States Food and Drug Administration
chemical_list: D053961:Azabicyclo Compounds; D006993:Hypnotics and Sedatives; D010879:Piperazines; D000069582:Eszopiclone